Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Zvi Yammer who wrote (2417)	7/19/1999 10:47:00 PM
From: Walter Morton	Respond to of 2742

I would have preferred the $100 Million or was it $125 Million instead of the $25 Million or was it $21 Million minus the time value of money. Even if they had the extra money or IMNX share, it still would come down to what difference would it have made? Would CIST have gotten the $31 Million agreement with PMC sooner? Would the Phase II clinical trials (in Australia) be finished faster? Would CIST have kept the part of its business that it sold to Techne? Would CIST have become profitable more quickly? Would Sales have increased? Would the market have valued CIST at something closer to book value? I don't think it would have made a difference. CIST has always appeared to have been run like a university research department. That is to say, THEIR MARKETING DEPARTMENT HAS BEEN INVISIBLE! Maybe Genome Securities is CIST's Marketing Department.